Krystal Biotech's KB113 shrinks 83.1% of assessed basal cell carcinoma lesions in Gorlin syndrome pilot study
KRYS•Krystal Biotech reported regression in 83.1% of assessed basal cell carcinoma lesions in a three-patient Gorlin syndrome pilot study of KB113. Non-injected lesions had an 85.1% regression rate, and the company has begun discussions with the FDA about advanced clinical development.
1. Pilot study results
Krystal Biotech reported regression in 83.1% of assessed basal cell carcinoma lesions in a three-patient Gorlin syndrome pilot study of KB113. Non-injected lesions had an 85.1% regression rate, and biopsies confirmed complete tumor clearance in one injected lesion from each patient. Reported adverse events were mild or moderate, transient and resolved during the study. The company has begun discussions with the FDA on advanced clinical development of KB113 for Gorlin syndrome.
